<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572088</url>
  </required_header>
  <id_info>
    <org_study_id>ABC-223-DE</org_study_id>
    <nct_id>NCT03572088</nct_id>
  </id_info>
  <brief_title>Terlipressin Infusion During Whipple Procedure: Effect on Blood Loss and Transfusion Needs</brief_title>
  <official_title>Terlipressin Infusion During Whipple Procedure: Effect on Blood Loss and Transfusion Needs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to look at the effect of terlipressin infusion on blood loss and blood
      transfusion needs during Whipple procedure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>intaoperative periods</time_frame>
    <description>Amount of intraoperative blood loss in ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients needing blood transfusion</measure>
    <time_frame>intaoperative periods</time_frame>
    <description>Number of patients needing blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell units transfused</measure>
    <time_frame>intaoperative periods</time_frame>
    <description>The number of red blood cell units transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portal pressure changes</measure>
    <time_frame>intaoperative periods</time_frame>
    <description>portal pressure changes in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>postoperative periods</time_frame>
    <description>ICU stay in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Terlipressin</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Terlipresssin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)</description>
    <arm_group_label>Terlipresssin</arm_group_label>
    <other_name>glypressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>0.9 Nacl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients older than 18 years of age,

          -  ASA classification class I and II,

          -  Patients assigned for Whipple procedure.

        Exclusion Criteria:

          -  Preoperative renal failure,

          -  Severe liver dysfunction (Child-Turcotte-Pugh grade C),

          -  Hyponatremia (Na+ &lt;132mmol/l),

          -  Severe valvular heart disease,

          -  Heart failure,

          -  Symptomatic coronary heart disease,

          -  Bradycardic arrhythmia (heart rate &lt; 60/min),

          -  Peripheral artery occlusive disease (clinical stadium II-IV),

          -  Uncontrolled arterial hypertension (Blood pressure &gt;160/100mmHg despite intensive
             treatment),

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assiut University hospital Egypt, Egypt</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 17, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Magdy Mohammed Mahdy Sayed</investigator_full_name>
    <investigator_title>Assiut-Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

